This article provides a comprehensive overview of pernicious anemia, covering its causes, symptoms, risk factors, diagnosis, treatment options, and prevention strategies
One area of research is dual agonists that target both GLP-1 and glucagon receptors that have the potential to provide enhanced metabolic benefits and more significant weight reduction
The DECLARE-TIMI 58 trial showed Farxiga users typically lose 3-5 kg (roughly 4-6 lb) in year one, with a plateau at maintenance levels thereafter
Experimental data indicate increased functional tone of the lower esophageal and pyloric sphincters following peptide administration, a response associated with reduced reflux-related injury and attenuation of esophageal inflammation in animal models (11)
Recently, a pediatric case prompted inquiry into the use of peptides, including BCP-157, to accelerate recovery from an overuse injury in a 12-year-old athlete
Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials